M icroRNAs (miRNAs) are a class of short RNA molecules that have fundamental roles in post-transcriptional regulation of gene expression.
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To clarify whether the altered circulating miRNA profile in ICH was unique, we also analyzed the plasma miRNA from 16 ischemic stroke patients with a similar risk profile (Tables  I and III in the online-only Data Supplement). We found that among the 30 upregulated miRNAs in ICH, 13 miRNAs (43%) were not changed in ischemic patients ( Figure 1C ; Table IV in the online-only Data Supplement).
To confirm the microarray data, we selected miR-29b, miR-365, miR-27a, miR-150*, miR-34c-3p, and miR-24, and performed quantitative polymerase chain reaction assays. Using standard curve method, we showed that the quantitative polymerase chain reaction results exhibited the same trend as the microarray data ( Figure 2 ). We further validated these findings in a separate validation cohort (Table II in the online-only Data Supplement). We showed that the plasma levels of miR-27a, miR-365, miR-150*, and miR-34c-3p were significantly increased in patients with ICH, whereas the change of miR-29b did not reach a significance ( Figure  I in the online-only Data Supplement). Then we performed functional annotation analysis and found that the most significantly over-represented biological processes in association with the deregulated miRNAs were inflammatory disease and inflammatory response (Figure II and Table V in the onlineonly Data Supplement).
To examine whether disease conditions may disturb miRNA compartmentalization in the plasma, we isolated microvesicles and analyzed the relative abundance of miRNAs in the particulate and supernatant fractions with quantitative polymerase chain reaction. In plasma from healthy controls, miRNAs could not be detected in the supernatant fraction but were present exclusively in the microvesicle fraction ( Figure 3A ). In contrast, these miRNAs were present in both the supernatant and the microvesicle fractions in the plasma from stroke patients ( Figure 3B ).
Discussion
In this study, we showed that the circulating miRNA levels in patients with ICH exhibited a unique pattern of change as compared with healthy controls. To eliminate possible effects of confounding factors, such as age and blood pressure, we also included an ischemic stroke group with comparable clinical parameters as ICH. We found that 13 deregulated miRNAs were unique to ICH and not found to be altered in ischemic stroke. These results suggested that the altered circulating miRNA profile after ICH was unlikely to be because of clinical complications caused by neurological deficits. Moreover, we confirmed the trend of changes in circulating miRNAs after ICH in a separate validation cohort with similar clinical conditions (except for the higher systolic blood pressure in ICH subjects). Likewise, a recent microarray study showed that multiple circulating miRNAs are differentially expressed in ICH patients with or without secondary hematoma enlargement. 7 Bioinformatics analysis of the present data suggested that the upregulated miRNA species were specifically enriched in biological processes of inflammatory disease and inflammation response. This result is consistent with a previous study on mRNA expression of inflammation-related genes, showing that a complex inflammatory response is present after experimental ICH. 8 A limitation of the present study, however, was that we could not completely exclude the potential impacts of certain confounding factors, such as systolic blood pressure on circulating miRNAs.
Recent studies have provided evidence that miRNAs in the plasma are encapsulated in membranous microvesicles and thereby protected from degradation. 2 Using quantitative polymerase chain reaction, we confirmed that in healthy controls, the selected miRNAs were only detectable in the microvesicle fraction of plasma. Interestingly, in the ICH plasma, we found that the upregulated miRNAs existed in both the microvesicle and the supernatant fractions, suggesting that the disease condition had impacts on both the total concentration of miRNAs and their association with microvesicles in plasma. It should be noted that the Figure 1 . Microarray profiling analysis of circulating microRNAs (miRNAs) in plasma from both hemorrhagic (Hemo, n=15) and ischemic (Isch, n=16) stroke patients as compared with healthy controls (n=8). Plasma samples were pooled for each cohort. A, Number of altered miRNAs with a change of ≥2-fold in male and female patients (MP and FP). B, Left, cluster analysis of all siRNAs detectable in the plasma (with at least 1 P call) from controls and hemorrhagic patients. Right, cluster analysis of the 30 miRNAs that were consistently upregulated in both male and female hemorrhagic patients. The color gradient represents relative expression level. C, The number of miRNAs that were altered in hemorrhagic and ischemic patients and those altered in both. FC indicates female control; and MC, male control. The origin of the increased miRNAs in ICH plasma remains to be identified. Stroke patients are associated with a systemic inflammatory status. 10, 11 Interestingly, it is noted that a number of the upregulated miRNAs in ICH plasma are inflammatory cell-derived miRNAs, including miR-150, miR-365, miR-30c, miR-27a, miR-574-5p, miR-130a, and miR-423. [12] [13] [14] Taken together, it is likely that the upregulated circulating mRNAs after ICH may be a result of increased microvesicle release from inflammatory cells. 13, 14 In addition, the circulating miRNAs can also be released from mechanically destructed blood vessel cells and injured neural cells caused by ICH.
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SUPPLEMENTAL MATERIAL Supplemental Methods
Sample collection and processing
Patients with spontaneous ICH diagnosed by multi-detector-row computed tomography scanning were included in the study. Healthy volunteers were used as controls. Peripheral blood samples were collected between 1 to 14 days after symptom onset (median 6 days).
Blood samples were processed as described 1 . Briefly, whole blood was centrifuged at 1600 g for 10 min, and then the supernatant was transferred into a fresh tube and further centrifuged at 13000 g for 10 min. The clear plasma was aliquoted into 1. 
miRNA microarray analysis
Total RNA isolated from 1 ml plasma of each subject was resuspended in 25 µl of water, and then each sample was assigned into one of six pools (control, ICH and ischemic stroke, males and females separately). A fixed volume of the pooled RNA sample was withdrawn from each pool and used for microarray detection. Microarray analysis was performed using Agilent Human miRNA Microarray Release 14.0, 8×15K arrays using standard labeling, hybridization and scanning protocols (ShanghaiBio Corporation, China). The raw data were processed and analyzed with Agilent GeneSpring GX software.
Bioinformatics analysis
Potential target genes for each miRNA were predicted with five independent bioinformatics tools: miRanda, MirTarget2, PITA, RNAhybrid and TargetScan. For each miRNA, potential target genes with at least 3 positive hits as predicted by five independent bioinformatics tools were included. Functional analysis and network construction for the regulated miRNAs were performed with Cytoscape and Ingenuity Pathways Analysis (IPA) softwares.
Quantitative real-time PCR (qPCR)
Total RNA extracted from 1 ml plasma was resuspended in 200 µl water, of which 5 µl was withdrawn and used for reverse transcription using TaqMan MicroRNA Reverse Transcription reagents and sequence-specific looped primers (Applied Biosystems) in a 15-µl reaction volume. 3 µl of the RT product was then used for real time PCR analysis using TaqMan MicroRNA Assay primer-probe sets with an ABI Prism 7700 system (Applied Biosystems). Standard curves were constructed for each specific miRNA using synthetic RNA molecules (from TaKaRa Biotechnology). Linear regression analysis confirmed that there was a highly significant linear relationship between the C t values from each PCR reaction with the logarithm of the copy number of input RNA template (r 2 values ranged from 0.978 to 1.000). For validation experiments, total RNA was converted to cDNA with miRCURY LNA Universal cDNA Synthesis Kit (Exiqon), and PCR performed with the predesigned LNA-enhanced microRNA primer sets and SYBR Green master mix (Exiqon). A spike-in miRNA of 5 × 10 8 copies were added directly into 300 µl of plasma sample before RNA extraction and used as an internal control.
Isolation and characterization of microvesicles
Isolation of microvesicles from plasma was performed as described 2 . Briefly, fresh plasma was centrifuged at 500 g for 30 min, followed by 12,000 g for 45 min. 
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). Differences between groups were analyzed with unpaired t-test between two groups. Statistical analysis was performed with GraphPad Prism. A value of P < 0.05 was regarded as statistically significant.
Supplemental Data
Supplemental BMI > 25. Data were presented as mean ± SEM. * P < 0.05 vs control, † P < 0.05 vs hemorrhagic group, one-way ANOVA followed by Tukey's test. 
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